A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to
evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical
activity of AB308 in combination with zimberelimab (AB122) in participants with advanced
malignancies.